Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer (Q33366100)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

author name string

Johan Vansteenkiste

1

1 reference

Europe PubMed Central

26 July 2017

Jean-Luc Canon

2

1 reference

Europe PubMed Central

26 July 2017

Henrik Riska

3

1 reference

Europe PubMed Central

26 July 2017

Robert Pirker

4

1 reference

Europe PubMed Central

26 July 2017

Patrick Peterson

5

1 reference

Europe PubMed Central

26 July 2017

William John

6

1 reference

Europe PubMed Central

26 July 2017

Pekka Mali

7

1 reference

Europe PubMed Central

26 July 2017

Michael Lahn

8

1 reference

Europe PubMed Central

26 July 2017

publication date

1 June 2005

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

23

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

263-269

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-005-6736-x

0 references

Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Her2-neu: a target in lung cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

State-of-the-art treatment for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense oligonucleotides in the treatment of non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel targets for lung cancer therapy: part I.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense therapy in oncology: new hope for an old idea?

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The potential of protein kinase C as a target for anticancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/15868384

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-6736-X

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33366100&oldid=1620883332"